(Bloomberg) -- UnitedHealth Group Inc., the biggest U.S.
health insurer by sales, picked Gilead Sciences Inc.’s Harvoni
as its preferred hepatitis C treatment, according to a person
familiar with the matter.
The decision applies to UnitedHealth’s fully insured
commercial customers, as well as to Medicaid and Medicare
members. The Minnetonka, Minnesota-based insurer has about 45
million U.S. health-plan customers, though not all follow the
company’s drug picks.
Labels: Harvoni, insurance coverage, UnitedHealth